You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: AEON IMAGING LLC Topic: W
Summary Recentlywe found extensive remodeling of the microvasculature of the retinaoccurring in some diabetic patients much earlier than expectedThis provides the potential for novel biomarkers to improve classification of patients for management and cost effective testing of therapiesHoweverthe equipment is too expensive for most clinics and small practicesThese early retinal microvascular change ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: SIGNAL SOLUTIONS, LLC Topic: NHLBI
ABSTRACTSignal Solutions has developed a novelnoninvasive and automated piezoelectric based sleep detection system for high throughput studies of sleep in miceand has recently expanded to rat studies as wellThe respiratory signal detected by the piezo sensor during sleep can be applied to investigate important health conditions including respiratory depression due to disease or drug useand other s ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: SIGNAL SOLUTIONS, LLC Topic: 100
Noninvasive Seizure Screening in Preclinical Models of Epilepsy There is an urgent need for research into treatment options for epilepsy and other seizure disordersAnimal models are increasingly used to understand disease mechanisms and to screen promising therapeutic approachesAnimal epilepsy model use typically requires expensive and labor intensive experimentationwith invasive EEG measurements ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: NEUROFIELDZ INC. Topic: NEI
Amblyopia is the most common cause of monocular visual impairment in children and young adultsaffectingpeopleAmblyopia is generally treated with patching or atropine therapyhowever these treatments are not effective in adults and up to half of juvenile casesoften because of poor complianceand cannot easily be personalized during therapyThese factors have led to recent interest in customized game b ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: BioTime, Inc. Topic: 100
ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: INTELON OPTICS, INC. Topic: N
ABSTRACT The overall goal of this STTR project is to commercialize a novel optical eye scanner device capable of measuring the biomechanical properties of tissues via Brillouin light scatteringThe Brillouin technology invented in the co PI s lab has shown broad potential for improving the diagnosis and treatment of vision disordersClinical data obtained with current laboratory systems revealed cor ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: RITHIM BIOLOGICS INC Topic: NCATS
ABSTRACT Atrial fibrillationAFis the most common rhythm disturbance in the US and other developed countriesAF significantly affects the lives of the afflictedcausing symptoms that range from palpitations to fatigueweakness and activity intoleranceand substantially increasing the risks of strokecongestive heart failure and deathThe impact on public health is substantialwith more thanhospital admiss ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Mitigation of Acute and Chronic Kidney Injuries by Systemic Infusion of Adipose-Derived Soluble Therapeutic Factor ConcentrateSBC: NeuroFx, Inc. Topic: 300
ABSTRACT Acute kidney injuryAKIis a syndrome characterized by rapid loss of the kidneyandapos s excretory functionAKI is the leading cause of nephrology consultation and results inmillion hospital admissions a yearThe socioeconomic impact of AKI is significantresulting in $billion cost to the health care systemDespite the high rate of incidence of AKIno therapy currently existsother than supportiv ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBI
Idiopathic pulmonary fibrosisIPFthe most common of the interstitial lung diseasesoccurs in aboutpeoplewithnew cases diagnosed annually in the USThe typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandaposof the lungs causing an irreversible loss of the tissueandapos s ability to transport oxygenCo morbid pulmonary hypertension is commonly seen in ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Chronic intrapulmonary delivery of a novel small molecule Wnt/beta-catenin inhibitor for Idiopathic Pulmonary FibrosisSBC: BETA CAT PHARMACEUTICALS, INC. Topic: NHLBI
Project Summary Idiopathic pulmonary fibrosisIPFis a devastatingprogressive disease with no known cure and no treatment that convincingly alters the disease course or significantly improves mortalityThe objective of this proposal is the development of nebulized delivery of the small molecule inhibitor of Wntcatenin signalingBCfor Idiopathic Pulmonary FibrosisPre clinical studies in rodentsdogsand ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health